Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Aug 7;23:287. doi: 10.1186/s12933-024-02386-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 2 — New-onset diabetes mellitus (NODM) among the patients who received a high-intensity statin according to the statin type. (A) The incidence of NODM in overall patients receiving high-intensity statin therapy. (B) Cubic spline analysis of the risk of NODM in the rosuvastatin group versus atorvastatin group according to the achieved LDL-C levels. (C) The incidence of NODM in the patients with achieved LDL-C levels < 70 mg/dL. (D) The incidence of NODM in the patients with achieved LDL-C levels ≥ 70 mg/dL. From the cubic spline analysis plotting (B), an increase of NODM in the rosuvastatin group versus atorvastatin group began below an achieved LDL-C level of 70 mg/dL (red arrow), which was determined as a cut-off value. CI = confidence interval; HR = Hazard ratio; LDL-C = low-density lipoprotein cholesterol